Related Experiment Video
Updated: Jan 29, 2026
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Detecting EGFR Gene Mutations on a Nanobioarray Chip
Fang Xu1, Montek Boparai1, Christopher Oberc1
1Department of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.
Abstract:
In this study, three point mutations of EGFR relevant to lung cancer therapy are detected. Mutated EGFR is the target of a therapy for non-small cell lung cancer (NSCLC) using tyrosine kinase inhibitors (TKIs) as treatment drugs. Background/Objectives: Point mutations in exon 21 (L858R and L861Q) of the EGFR gene are TKI-sensitive; however, mutations in exon 20 (T790M) are TKI-resistant. Therefore, a fast detection method that classifies an NSCLC patient to be drug sensitive or drug resistant is highly clinically relevant. Methods: Probes were designed to detect three point mutations in genomic samples based on DNA hybridization on a solid surface. A method has been developed to detect single nucleotide polymorphism (SNP) for these mutation detections in the 16-channel nanobioarray chip. The wash by gold-nanoparticles (AuNP) was used to assist the differentiation detection. Results: The gold nanoparticle-assisted wash method has enhanced differentiation between WT and mutated sequences relevant to the EGFR sensitivity to tyrosine kinase inhibitors. Conclusions: The WT and mutated sequences (T790M, L858R and L861Q) in genomic samples were successfully differentiated from each other.
Insights
A new method detects EGFR mutations for lung cancer therapy. This gold nanoparticle-assisted technique differentiates drug-sensitive and drug-resistant non-small cell lung cancer (NSCLC) mutations, aiding treatment decisions.
Area of Science:
- Biochemistry
- Molecular Biology
- Genetics
Background:
- Epidermal Growth Factor Receptor (EGFR) mutations are key targets in non-small cell lung cancer (NSCLC) therapy.
- Tyrosine Kinase Inhibitors (TKIs) are used to treat NSCLC, with efficacy dependent on specific EGFR mutations.
- Exon 21 mutations (L858R, L861Q) are TKI-sensitive, while Exon 20 (T790M) mutations confer TKI resistance.
Purpose of the Study:
- To develop a rapid detection method for classifying NSCLC patients based on EGFR mutation status.
- To differentiate between TKI-sensitive and TKI-resistant EGFR mutations for personalized therapy.
Main Methods:
- Design of DNA probes for detecting three specific EGFR point mutations (T790M, L858R, L861Q).
- Utilizing a 16-channel nanobioarray chip for single nucleotide polymorphism (SNP) detection via DNA hybridization.
- Employing a gold nanoparticle (AuNP)-assisted wash step to enhance differentiation.
Main Results:
- Successful differentiation between wild-type (WT) and mutated EGFR sequences.
- Enhanced discrimination of TKI-sensitive (L858R, L861Q) and TKI-resistant (T790M) mutations.
- Demonstrated efficacy of the AuNP-assisted wash in improving detection accuracy.
Conclusions:
- The developed nanobioarray method reliably differentiates WT and key EGFR mutations (T790M, L858R, L861Q) in genomic samples.
- This method provides a foundation for rapid clinical classification of NSCLC patients.
- Facilitates informed treatment decisions based on EGFR mutation profiles for improved therapeutic outcomes.
Related Concept Videos
01:09Mutation, Gene Flow, and Genetic Drift
01:39Mutations
01:35Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
00:36Viral Mutations
00:59Gene Therapy
02:39Gene Flow